{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:12:28Z","timestamp":1790835148328,"version":"4.1.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00529","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T09:13:24Z","timestamp":1528190004000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":96,"title":["Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes"],"prefix":"10.3389","volume":"9","author":[{"given":"Deborah C.","family":"Mash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Allen-Ferdinand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine.","volume":"8","author":"Alper","year":"1999","journal-title":"Am. J. Addict."},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jep.2007.08.034","article-title":"The ibogaine medical subculture.","volume":"115","author":"Alper","year":"2008","journal-title":"J. Ethnopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1556-4029.2011.02008.x","article-title":"Fatalities temporally associated with the ingestion of ibogaine.","volume":"57","author":"Alper","year":"2012","journal-title":"J. Forensic Sci."},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004147.pub3","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.","volume":"5","author":"Amato","year":"2008","journal-title":"Database Syst. Rev."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004147.pub3.","author":"Bastiaans","year":"2004","journal-title":"Life after Ibogaine: An Exploratory Study of the Long-Term Effects of Ibogaine Treatment on Drug Addicts"},{"key":"B6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-3565(24)29567-7","article-title":"In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats.","volume":"297","author":"Baumann","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of beck depression inventories-IA and -II in psychiatric outpatients.","volume":"67","author":"Beck","year":"","journal-title":"J. Pers. Assess."},{"key":"B8","author":"Beck","year":"","journal-title":"Manual for the Beck Depression Inventory-II"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.71","article-title":"Ibogaine and addiction in the animal model, a systematic review and meta-analysis.","volume":"6","author":"Belgers","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2017.1320802","article-title":"Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.","author":"Brown","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database.","volume":"341","author":"Cornish","year":"2010","journal-title":"Br. Med. J."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1556\/2054.01.2017.009","article-title":"Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning.","volume":"1","author":"Davis","year":"2017","journal-title":"J. Psych. Stud."},{"key":"B13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"B14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0099-9598(01)56017-4","article-title":"\u201cReturning to the path\u201d: the use of iboga[ine] in an equatorial African ritual context and the binding of time, space, and social relationships.","volume":"56","author":"Fernandez","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jad.2004.12.011","article-title":"The validity of the beck depression inventory-short form as a screening and diagnostic instrument for moderate and severe depression in medical inpatients.","volume":"86","author":"Furlanetto","year":"2005","journal-title":"J. Affect. Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0006-8993(94)90948-2","article-title":"Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.","volume":"657","author":"Glick","year":"1994","journal-title":"Brain Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1749-6632.2000.tb05211.x","article-title":"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.","volume":"914","author":"Glick","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jcph.404","article-title":"Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability.","volume":"55","author":"Glue","year":"","journal-title":"J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/jcph.471","article-title":"Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.","volume":"55","author":"Glue","year":"","journal-title":"J. Clin. Pharmacol."},{"key":"B20","first-page":"70","article-title":"Pharmacodynamics and therapeutic applications of iboga and ibogaine.","volume":"6","author":"Goutarel","year":"1993","journal-title":"Psych. Monogr. Essays"},{"key":"B21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0899-3289(95)90017-9","article-title":"Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey.","volume":"7","author":"Grant","year":"1995","journal-title":"J. Subst. Abuse"},{"key":"B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0010-440X(91)90066-L","article-title":"The measurement of craving in cocaine patients using the Minnesota cocaine craving scale.","volume":"32","author":"Halikas","year":"1991","journal-title":"Comp. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal.","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am. J. Alcohol Abuse"},{"key":"B24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jat\/19.6.427","article-title":"Identification and quantitation of ibogaine and an O-demethylated metabolite in brain and biological fluids using gas chromatography\/mass spectrometry.","volume":"19","author":"Hearn","year":"1995","journal-title":"J. Anal. Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0888-7543(05)80282-4","article-title":"Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.","volume":"14","author":"Heim","year":"1992","journal-title":"Genomics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jsat.2006.05.009","article-title":"Heroin and cocaine craving and use during treatment: measurement validation and potential relationships.","volume":"31","author":"Heinz","year":"2006","journal-title":"J. Subst. Abuse Treat."},{"key":"B27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1056\/NEJMc0804248","article-title":"Long-QT syndrome induced by the antiaddiction drug ibogaine.","volume":"360","author":"Hoelen","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1124\/jpet.102.038240","article-title":"Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.","volume":"303","author":"Katchman","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2007.9.2\/hkleber","article-title":"Pharmacologic treatments for opioid dependence: detoxification and maintenance options.","volume":"9","author":"Kleber","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1369-1600.2012.00447.x","article-title":"Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.","volume":"19","author":"Koenig","year":"2014","journal-title":"Addict. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu. Rev. Public Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/jat\/30.7.434","article-title":"Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub.","volume":"30","author":"Kontrimavici","year":"2006","journal-title":"J. Anal. Toxicol."},{"key":"B33","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/medicina44120123","article-title":"Acute toxicity of ibogaine and noribogaine.","volume":"44","author":"Kubiliene","year":"2008","journal-title":"Medicina"},{"key":"B34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1360-0443.2008.02455.x","article-title":"Buprenorphine tapering schedule and illicit opioid use.","volume":"104","author":"Ling","year":"2009","journal-title":"Addiction"},{"key":"B35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0099-9598(01)56020-4","article-title":"Case studies of ibogaine treatment: implications for patient management strategies.","volume":"56","author":"Lotsof","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"key":"B36","article-title":"Rapid method for interrupting the narcotic addiction syndrome.","author":"Lotsof","year":"1985"},{"key":"B37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1521-0391.1998.tb00472.x","article-title":"Observations on treatment with ibogaine.","volume":"7","author":"Luciano","year":"1998","journal-title":"Am. J. Addict."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2017.1357184","article-title":"Breaking the cycle of opioid use disorder with ibogaine.","author":"Mash","year":"2018","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B39","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1177\/0269881116641331","article-title":"Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.","volume":"30","author":"Mash","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1749-6632.1998.tb08242.x","article-title":"Medication development of ibogaine as a pharmacotherapy for drug dependence.","volume":"844","author":"Mash","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0099-9598(01)56012-5","article-title":"Ibogaine in the treatment of heroin withdrawal.","volume":"56","author":"Mash","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","article-title":"Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.","volume":"914","author":"Mash","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0024-3205(95)00273-9","article-title":"Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.","volume":"57","author":"Mash","year":"1995","journal-title":"Life Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index.","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abuse Treat."},{"key":"B45","author":"McLellan","year":"1999","journal-title":"Addiction Severity Index Lite-CF. Clinical\/Training Version"},{"key":"B46","author":"Murdock","year":"1987","journal-title":"Outline of Cultural Materials (HRAF Manuals)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.","volume":"44","author":"Noller","year":"2018","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","article-title":"Treatment of depression in patients with alcohol and other drug dependence: a Meta-analysis.","volume":"291","author":"Nunes","year":"2004","journal-title":"JAMA"},{"key":"B49","first-page":"1359","article-title":"Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.","volume":"25","author":"Obach","year":"1998","journal-title":"Drug Metab. Disposition"},{"key":"B50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0031-6997(25)06842-5","article-title":"100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.","volume":"47","author":"Popik","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths\u2013United States, 2000\u20132014.","volume":"64","author":"Rudd","year":"2016","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"B52","first-page":"105","article-title":"The Bwiti religion and the psychoactive plant Tabernathe iboga (Equatorial Africa).","volume":"5","author":"Samorini","year":"1995","journal-title":"Integration"},{"key":"B53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0740-5472(94)90049-3","article-title":"A preliminary investigation of ibogaine: case reports and recommendations for further study.","volume":"11","author":"Sheppard","year":"1994","journal-title":"J. Subst. Abuse Treat."},{"key":"B54","author":"Singelton","year":"1998","journal-title":"Hcq-now-sf-14R: Revised Version of the Heroin Craving Questionnaire \u2013 Brief"},{"key":"B55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/BF02805969","article-title":"Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.","volume":"127","author":"Staley","year":"1996","journal-title":"Psychopharmacology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0376-8716(93)90042-O","article-title":"The development of a cocaine craving questionnaire.","volume":"34","author":"Tiffany","year":"1993","journal-title":"Drug Alcohol Depend."},{"key":"B57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1126\/science.308.5720.345","article-title":"Addiction research. Ibogaine therapy: a \u2018vast, uncontrolled experiment\u2019.","volume":"308","author":"Vastag","year":"2005","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2013tackling the opioid-overdose epidemic.","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T23:55:23Z","timestamp":1751673323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":58,"alternative-id":["10.3389\/fphar.2018.00529"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00529","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]},"article-number":"529"}}